Budget impact analysis of drugs for ultra-orphan non-oncological diseases in Europe
Background/aim: Ultra-orphan diseases (UODs) have been defined by a prevalence of less than 1 per 50,000 persons. However, little is known about budget impact of ultra-orphan drugs. Methods: For analysis, the budget impact analysis (BIA) had a time horizon of 10 years (2012-2021) and a pan-European...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2015
|
| In: |
Expert review of pharmacoeconomics and outcomes research
Year: 2015, Jahrgang: 15, Heft: 1, Pages: 171-179 |
| ISSN: | 1744-8379 |
| DOI: | 10.1586/14737167.2015.965156 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1586/14737167.2015.965156
|
| Verfasserangaben: | Michael Schlander, Charles Christian Adarkwah and Afschin Gandjour |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1562792679 | ||
| 003 | DE-627 | ||
| 005 | 20241209150040.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 170828s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1586/14737167.2015.965156 |2 doi | |
| 035 | |a (DE-627)1562792679 | ||
| 035 | |a (DE-576)492792674 | ||
| 035 | |a (DE-599)BSZ492792674 | ||
| 035 | |a (OCoLC)1340978950 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Schlander, Michael |d 1959- |e VerfasserIn |0 (DE-588)1036904652 |0 (DE-627)751411957 |0 (DE-576)389587710 |4 aut | |
| 245 | 1 | 0 | |a Budget impact analysis of drugs for ultra-orphan non-oncological diseases in Europe |c Michael Schlander, Charles Christian Adarkwah and Afschin Gandjour |
| 264 | 1 | |c 2015 | |
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online veröffentlicht: 14. Oktober 2014 | ||
| 500 | |a Gesehen am 28.08.2017 | ||
| 520 | |a Background/aim: Ultra-orphan diseases (UODs) have been defined by a prevalence of less than 1 per 50,000 persons. However, little is known about budget impact of ultra-orphan drugs. Methods: For analysis, the budget impact analysis (BIA) had a time horizon of 10 years (2012-2021) and a pan-European payer’s perspective, based on prevalence data for UODs for which patented drugs are available and/or for which drugs are in clinical development. Results: A total of 18 drugs under patent protection or orphan drug designation for non-oncological UODs were identified. Furthermore, 29 ultra-orphan drugs for non-oncological diseases under development that have the potential of reaching the market by 2021 were found. Total budget impact over 10 years was estimated to be €15,660 and €4965 million for approved and pipeline ultra-orphan drugs, respectively (total: €20,625 million). Conclusion: The analysis does not support concerns regarding an uncontrolled growth in expenditures for drugs for UODs. | ||
| 650 | 4 | |a budget impact analysis | |
| 650 | 4 | |a drugs | |
| 650 | 4 | |a Europe | |
| 650 | 4 | |a non-oncological diseases | |
| 650 | 4 | |a ultra-orphan | |
| 700 | 1 | |a Adarkwah-Yiadom, Charles Christian |d 1982- |e VerfasserIn |0 (DE-588)143317164 |0 (DE-627)644731966 |0 (DE-576)33622110X |4 aut | |
| 700 | 1 | |a Gandjour, Afschin |d 1968- |e VerfasserIn |0 (DE-588)124867006 |0 (DE-627)367231964 |0 (DE-576)294542302 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert review of pharmacoeconomics and outcomes research |d Abingdon : Taylor & Francis Group, 2001 |g 15(2015), 1, Seite 171-179 |h Online-Ressource |w (DE-627)35569042X |w (DE-600)2090846-5 |w (DE-576)284039519 |x 1744-8379 |7 nnas |a Budget impact analysis of drugs for ultra-orphan non-oncological diseases in Europe |
| 773 | 1 | 8 | |g volume:15 |g year:2015 |g number:1 |g pages:171-179 |g extent:10 |a Budget impact analysis of drugs for ultra-orphan non-oncological diseases in Europe |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1586/14737167.2015.965156 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1586/14737167.2015.965156 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20170828 | ||
| 993 | |a Article | ||
| 994 | |a 2015 | ||
| 998 | |g 1036904652 |a Schlander, Michael |m 1036904652:Schlander, Michael |d 60000 |d 65300 |e 60000PS1036904652 |e 65300PS1036904652 |k 0/60000/ |k 1/60000/65300/ |p 1 |x j | ||
| 999 | |a KXP-PPN1562792679 |e 2978653167 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"type":{"bibl":"article-journal","media":"Online-Ressource"},"physDesc":[{"extent":"10 S."}],"language":["eng"],"person":[{"family":"Schlander","role":"aut","given":"Michael","display":"Schlander, Michael"},{"given":"Charles Christian","role":"aut","family":"Adarkwah-Yiadom","display":"Adarkwah-Yiadom, Charles Christian"},{"family":"Gandjour","given":"Afschin","role":"aut","display":"Gandjour, Afschin"}],"title":[{"title_sort":"Budget impact analysis of drugs for ultra-orphan non-oncological diseases in Europe","title":"Budget impact analysis of drugs for ultra-orphan non-oncological diseases in Europe"}],"name":{"displayForm":["Michael Schlander, Charles Christian Adarkwah and Afschin Gandjour"]},"recId":"1562792679","id":{"doi":["10.1586/14737167.2015.965156"],"eki":["1562792679"]},"origin":[{"dateIssuedKey":"2015","dateIssuedDisp":"2015"}],"note":["Online veröffentlicht: 14. Oktober 2014","Gesehen am 28.08.2017"],"relHost":[{"recId":"35569042X","disp":"Budget impact analysis of drugs for ultra-orphan non-oncological diseases in EuropeExpert review of pharmacoeconomics and outcomes research","id":{"issn":["1744-8379"],"zdb":["2090846-5"],"eki":["35569042X"]},"origin":[{"publisherPlace":"Abingdon ; London ; London ; London","publisher":"Taylor & Francis Group ; Future Drugs ; Expert Reviews ; Informa UK","dateIssuedKey":"2001","dateIssuedDisp":"2001-"}],"part":{"year":"2015","issue":"1","volume":"15","pages":"171-179","text":"15(2015), 1, Seite 171-179","extent":"10"},"type":{"media":"Online-Ressource","bibl":"periodical"},"note":["Gesehen am 17.05.18"],"pubHistory":["1.2001 -"],"language":["eng"],"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title_sort":"Expert review of pharmacoeconomics and outcomes research","title":"Expert review of pharmacoeconomics and outcomes research"}]}]} | ||
| SRT | |a SCHLANDERMBUDGETIMPA2015 | ||